MAP2K7 and hepatocellular carcinoma: In the present study, we investigated the therapeutic efficacy of sorafenib, regorafenib, the MEK inhibitor PD-0325901 (PD901), and the pan-mTOR inhibitor MLN0128 in vitro using HCC cell lines and in vivo using the AKT/c-MET preclinical HCC model.